接受或即将开始免疫抑制治疗者结核预防治疗的安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入27项研究共3184名接受或即将开始免疫抑制药物者,评估结核预防治疗(TPT)的不良事件相关停药比例。含利福霉素方案停药比例最低,但仅在开始免疫抑制前提供;单用异烟肼方案可在免疫抑制期间使用,停药比例为5.3%。
要点
- 含利福霉素方案不良事件相关停药比例最低(2.0%),但仅在免疫抑制前使用。
- 单用异烟肼方案可在免疫抑制期间使用,停药比例5.3%(95%CI 3.1-8.9%)。
- 生物制剂/激素与移植人群分层后停药比例相似。
核心结论
- TPT不良事件相关停药比例与更广泛TPT文献相似。
- 含利福霉素方案停药比例最低,但仅在开始免疫抑制前提供。
- 需要接受免疫抑制药物者使用非异烟肼方案的安全性数据。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Cochrane、Health Star和EMBASE(1952年至2025年5月1日)。
- 纳入27项研究,共3184名接受或即将开始免疫抑制药物者。
- 主要结局分析纳入25项研究、2802名参与者,采用随机效应广义线性混合模型及Hartung-Knapp 95%置信区间。
主要发现
- 单用异烟肼6-12个月方案(1511人)不良事件相关停药比例为5.3%(95%CI 3.1-8.9%;I2=65.4%)。
- 单用利福霉素4个月方案(228人)停药比例为4.4%(95%CI 0.1-75.4%;I2=86.3%)。
- 异烟肼-利福霉素联合3个月方案(990人)停药比例为2.0%(95%CI 1.0-4.1%;I2=0.0%)。
- 含氟喹诺酮6-9个月方案(73人)停药比例为6.9%(95%CI 0-92.3%;I2=65.4%)。
- 按生物制剂/激素与移植人群分层后,停药比例相似。
关键数值与推荐
- 单用异烟肼方案是唯一在免疫抑制期间提供的方案。
- 含利福霉素方案仅在开始免疫抑制前提供。
临床怎么用
- 接受免疫抑制药物者如需在免疫抑制期间行TPT,可考虑单用异烟肼方案,但需关注5.3%的不良事件相关停药比例。
- 如条件允许在开始免疫抑制前启动TPT,含利福霉素方案(尤其异烟肼-利福霉素联合)不良事件相关停药比例较低。
局限性
- 单用利福霉素和含氟喹诺酮方案样本量小、置信区间宽、异质性高。
- 接受免疫抑制药物期间使用非异烟肼方案的安全性数据缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People receiving immunosuppressive medications are at increased risk of tuberculosis. Tuberculosis preventive treatment (TPT) can reduce risk, however its safety among these populations is uncertain. We conducted a meta-analysis to evaluate adverse events (AE) associated with TPT among people receiving or about to initiate immunosuppressive medications. METHODS: We searched MEDLINE, Cochrane, Health Star, and EMBASE (1952-May 1, 2025), for studies reporting AE during TPT among people receiving or about to initiate immunosuppressives. We used random-effects generalized linear mixed models with Hartung-Knapp 95% confidence intervals to estimate our primary outcome: pooled proportion of AE-related discontinuation, stratified by TPT regimen. RESULTS: We included 27 studies (3184 participants). Populations included biologics/steroids recipients and solid organ/hematopoietic transplant candidates/recipients. For the primary outcome (25 studies, 2802 participants), TPT regimens included 6-12-month mono-isoniazid regimens (1511 participants), 4-months mono-rifamycin regimens (228 participants), 3-month isoniazid-rifamycin combination regimens (990 participants), and 6-9-month fluoroquinolone-based regimens (73 participants). Only mono-isoniazid regimens were provided while receiving immunosuppressives. Pooled AE-related discontinuation was 5.3% (95% CI: 3.1-8.9%; I2=65.4%) for mono-isoniazid regimens, 4.4% (95% CI: 0.1-75.4%; I2=86.3%) for mono-rifamycin regimens, 2.0% (1.0-4.1%; I2=0.0%) for isoniazid-rifamycin combination regimens, and 6.9% (95% CI: 0-92.3%; I2=65.4%) for fluoroquinolone-based regimens. Proportions were similar when stratified by biologics/steroids and transplant populations. CONCLUSION: Overall, AE-related TPT discontinuation was like the broader TPT literature. AE-related discontinuation of TPT was lowest with rifamycin-containing regimens, but these were only provided prior to initiating immunosuppressives. Data on the safety of non-isoniazid regimens among people receiving immunosuppressives are needed.
引用
- Selemon A, Fernandes ML, Romanowski K, et al. Safety of tuberculosis preventive treatment among people receiving or about to initiate immunosuppressive medications: a systematic review and meta-analysis. Clin Infect Dis. 2026. PMID: 42765630. doi:10.1093/cid/ciag584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。